Eli Lilly and Company (NYSE:LLY) is one of Goldman Sachs top healthcare stocks. On March 10, analysts at Bernstein SocGen reiterated an Outperform rating on Eli Lilly with a $1,300 price target. The positive stance comes on the heels of the company launching the Employer Connect platform to enhance access to its obesity medications through employer-sponsored programs.
Stokkete/Shutterstock.com
The company has already partnered with 15 program administrators, including GoodRx and Mark Cuban’s Cost Plus Drugs, to enable employers to activate the GLP-1 coverage insurance platform for their staff. The unveiling of the new platform is part of an effort to capitalize on limited commercial insurance coverage. The new platform will expand GLP-1 coverage by enabling employers to customize coverage and wraparound services for employees. It also provides a way to share costs and lower employer expenses.
The launch of the new platform follows Mounjaro’s prescription reaching 724,500 and 361,000 new prescriptions for the week ending February 27, affirming strong interest in the company’s GLP-1 medications.
Eli Lilly and Company is a global healthcare company that discovers, develops, manufactures, and markets human pharmaceutical products, focusing on areas like diabetes, obesity, oncology, and immunology.
READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 11 Best Affordable Growth Stocks to Buy Now.
